- Home
- CGO vs KZIA Comparison
CGO vs KZIA Comparison
Compare CGO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | KZIA |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.3M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | CGO | KZIA |
|---|---|---|
| Price | $12.52 | $12.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 29.0K | ★ 246.8K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.26 | $3.05 |
| 52 Week High | $12.79 | $17.40 |
Technical Indicators
Market Signals| Indicator | CGO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 74.00 |
| Support Level | $11.37 | $5.85 |
| Resistance Level | N/A | $14.42 |
| Average True Range (ATR) | 0.21 | 1.32 |
| MACD | 0.06 | 0.28 |
| Stochastic Oscillator | 92.01 | 97.31 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.